TGF-beta-specific antibodies and methods of use thereof for treatment
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jul 25, 2017
Issued Date -
N/A
app pub date -
Jul 24, 2015
filing date -
Jun 3, 2011
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present disclosure relates, in general, to materials and methods for antibodies specific for transforming growth factor beta (TGFβ), including TGFβ1, TGFβ2 and TGFβ3, and uses of these antibodies in the treatment of subjects having cancer, an eye disease, condition or disorder, fibrosis, including ophthalmic fibrosis or fibrosis of the eye, and other conditions or disorders related to TGFβ expression.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully